Abstract:  Soft tissue sarcomas (STS) are a rare group of mesenchymal malignancies except bone or cartilage, with a low incidence rate. Patients with advanced STS have limited treatment options, poor prognosis and high mortality. Recently, immune checkpoint inhibitors (ICIs) have made great breakthroughs in the field of tumor therapy, greatly improving the prognosis of patients with various malignancies. However, efficacy of ICIs in the treatment of STS remains unravelled. This review summarizes the role of the ICIs in various sets of advanced STS treatment and provides future research directions, hoping to serve as a reference for clinicians.

Key words:  , Soft tissue sarcomas">Soft tissue sarcomas')">">, Immune checkpoint inhibitors">Immune checkpoint inhibitors')">">, PD-1 inhibitor">PD-1 inhibitor')">">, PD-L1 inhibitor">PD-L1 inhibitor')">">, CTLA-4 inhibitor')">">CTLA-4 inhibitor